[{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Wockhardt","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Cefepime","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compounds","year":"2025","type":"Inapplicable","leadProduct":"18-F FPIA","moa":"Pyruvate kinase","graph1":"Oncology","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"AVM Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"AVM0703","moa":"Glucocorticoid receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Effector Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zotatifin","moa":"eIF4A","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"AVM Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"AVM0703","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Azeliragon","moa":"Advanced glycosylation end product-specific receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Edgewise Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Edgewise Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Edgewise Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Silence Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"SLN360","moa":"Apolipoprotein A messenger RNA (LPA mRNA)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Silence Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Zerlasiran","moa":"Lipoprotein","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Milestone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etripamil","moa":"coronary vasodilators (verapamil type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Lerodalcibep","moa":"Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Abaloparatide","moa":"Parathyroid hormone receptor","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Sirnaomics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STP707","moa":"TGF-beta-1\/COX-2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Powder For Injection","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Saniona","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SAN711","moa":"GABAA receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"},{"orgOrder":0,"company":"Medpace, Inc","sponsor":"Blue Earth Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compounds","year":"2024","type":"Inapplicable","leadProduct":"177-Lu rhPSMA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Medpace, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medpace, Inc \/ Medpace, Inc","highestDevelopmentStatusID":"6","companyTruncated":"Medpace, Inc \/ Medpace, Inc"}]
Find Clinical Drug Pipeline Developments & Deals by Medpace, Inc
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
